3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
2
CNS
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
Conditions
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
pembrolizumab
33
Injections
28
Pemetrexed
15
Interviews as Topic
15
Carboplatin
14
tislelizumab
13
Specimen Handling
13
Cisplatin
13
atezolizumab
11
Nivolumab
11
Bevacizumab
11
Practice Guidelines as Topic
9
Educational Status
9
Cyclophosphamide
9
Standard of Care
8
Oxaliplatin
8
Fluorouracil
8
fludarabine
7
Methods
7
Early Intervention, Educational
7
Docetaxel
7
Cetuximab
7
Capecitabine
7
toripalimab
6
sotorasib
6
Platinum
6
Paclitaxel
6
Leucovorin
6
Ipilimumab
6
olaparib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Influenza Vaccines
×
Other solid neoplasm
×
90 days
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled